Zai Lab under pressure over clinical results and rival drugs 產品增長疲軟核心臨床進展不順 再鼎醫藥遭遇挑戰
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products. 市場用腳投票的背后，是再鼎醫藥核心產品增長疲軟與研發管線受挫的雙重困境。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.